The Brazilian TP53 mutation (R337H) and sarcomas

Area of Science:

• Oncology
• Genetics
• Cancer Research

Background:

• Sarcomas are rare cancers, accounting for less than 1% of adult solid tumors but over 20% of childhood cancers.
• Genetic predisposition, particularly Li-Fraumeni Syndrome (LFS), is a significant factor in sarcoma etiology.
• Brazil exhibits a unique high prevalence of the TP53 p.Arg337His mutation, leading to a concentrated occurrence of LFS.

Purpose of the Study:

• To investigate the prevalence and impact of the Brazilian germline TP53 mutation (p.Arg337His) in a cohort of 502 unselected sarcoma patients.
• To determine the association between this specific TP53 mutation and sarcoma histology.
• To assess the implications for genetic counseling and patient management in sarcoma cases.

Main Methods:

• Analysis of 502 sarcoma patients, irrespective of age or family history.
• Screening for the p.Arg337His mutation in the TP53 gene.
• Histopathological classification of sarcoma subtypes in mutation carriers.

Main Results:

• The p.Arg337His TP53 mutation was identified in 8% of the studied sarcoma patients.
• Leiomyosarcoma was the predominant sarcoma subtype among mutation carriers, representing 52.5% of these cases.
• The findings indicate a significant role for this specific germline mutation in Brazilian sarcoma patients.

Conclusions:

• The p.Arg337His TP53 mutation is a relevant genetic factor in a notable proportion of Brazilian sarcoma patients.
• Identification of this mutation underscores the importance of genetic counseling for sarcoma patients and their families.
• These results can inform tailored management strategies for sarcoma patients, particularly in populations with a high prevalence of LFS.